Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity

Clinical Therapeutics

Volumn 22, Issue 8, 2000, Pages 911-936

  Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Adverse effect; Antiretroviral therapy; Lactic acidosis; Lipodystrophy; Mitochondria; Nucleoside analog

Indexed keywords

ANTIRETROVIRUS AGENT; MITOCHONDRIAL DNA; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADIPOCYTE; ARTICLE; COMPETITIVE INHIBITION; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; PERIPHERAL NEUROPATHY;

EID: 0033862761     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80064-8     Document Type: Article

References (137)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
3. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
4. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study
5. Maintenance antiretroviral therapies in HIV-infected patients with undetectable plasma HIV RNA after triple-drug therapy
6. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients
7. A risk-benefit assessment of HIV protease inhibitors
8. Mitochondrial toxicity of antiviral drugs
9. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
10. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: A looming obstacle for long-term anti-retroviral therapy?
11. Inhibition of HIV reverse transcriptase by 2',3'-dideoxynucleoside triphosphates
12. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
13. Biochemical pharmacology of (+)- and (-)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents
14. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis
15. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells
16. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
17. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
18. The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma
19. Lack of mitochondrial toxicity in CEM cells treated with carbovir
20. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity
21. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides
22. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells
23. Clinical mitochondrial genetics
24. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines
25. Disorders of the mitochondria
26. Mitochondrial encephalomyopathies
27. Treatment of mitochondrial disease
28. Nonrandom tissue distribution of mutant mtDNA
29. Neonatal Fanconi syndrome due to deficiency of complex III of the respiratory chain
30. Mitochondrial respiratory chain disorders and the liver
31. Neuropathology and pathogenesis of mitochondrial diseases
32. Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers' syndrome
33. Progressive poliodystrophy (Alpers' disease) with a defect in cytochrome aa3 in muscle: A report of two unrelated patients
34. Role and mechanisms of secondary mitochondrial failure
35. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: Ultrastructural and biochemical findings
36. Does hepatitis C cause liver injury by pathways associated with mitochondrial dysfunction?
37. Hydroxyurea and HIV: 5 Years later - From antiviral to immune-modulating effects
38. Hydroxyurea toxicity in human immunodeficiency virus-positive patients
39. A retrospective case-control study to determine if the addition of hydroxyurea to regimens that contain ddI or d4T or ddI and d4T increases the risk of developing peripheral neuropathy in HIV infected individuals
40. Hydroxyurea-induced neurotoxicity in HIV disease
41. Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients
42. Protective effect of P. fraternus against ethanol-induced mitochondrial dysfunction
43. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
44. Ongoing nucleoside safety review of HIV-exposed children in US studies
45. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management
46. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B: A randomized, double-blinded, placebo-controlled trial
47. The didanosine Expanded Access Program: Safety analysis
48. 2',3'-Dideoxycytidine (ddC) toxic neuropathy: A study of 52 patients
49. Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine
50. 2',3'-Dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial
51. 2',3'-Didehydro-3'-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase I trial
52. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection
53. The PC12 cell as a model for studies of mechanism of induction of peripheral neuropathy by anti-HIV-1 dideoxynucleoside analogs
54. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells
55. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues
56. The role of carnitine in intracellular metabolism
57. Neuroprotective activity of acetyl-L-carnitine: Studies in vitro
58. Long-term acetyl-L-carnitine treatment in Alzheimer's disease
59. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease
60. Nerve growth factor binding in aged rat central nervous system: Effect of acetyl-L-carnitine
61. Mitochondrial myopathy caused by long-term zidovudine therapy
62. Myopathies associated with human immunodeficiency virus and zidovudine: Can their effects be distinguished?
63. Early features of zidovudine-associated myopathy: Histopathological findings and clinical correlations
64. Dilated cardiomyopathy in a zidovudine-treated AIDS patient
65. Chronic lactic acidosis in a patient with acquired immunodeficiency syndrome and mitochondrial myopathy: Biochemical studies
66. Concurrent zidovudine-induced myopathy and hepatotoxicity in patients treated for human immunodeficiency virus (HIV) infection
67. Effect of zidovudine and didanosine treatment on heart function in children infected with human immmunodeficiency virus
68. Lack of muscle toxicity with didanosine (ddI). Clinical and experimental studies
69. AZT decreases rat myocardial cytochrome oxidase activity and increases beta-myosin heavy chain content
70. Mitochondrial myopathy caused by long-term zidovudine therapy
71. Ultra-structural characteristics and DNA immunocytochemistry in human immunodeficiency virus and zidovudine-associated myopathies
72. Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy
73. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts
74. Molecular mechanism of the short-term cardiotoxicity caused by 2',3'-dideoxycytidine (ddC): Modulation of reactive oxygen species levels and ADP-ribosylation reactions
75. Mitochondrial sensitivity to zidovudine
76. Prognosis in AZT myopathy
77. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage
78. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro
79. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves AZT-induced changes and prevents further destruction
80. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins
81. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
82. Emerging complication of antiretroviral therapy: Symptomatic hyperlactatemia
83. Hyperlactatemia and hepatic abnormalities in ten HIV-infected patients taking multiple nucleoside analogs
84. Lactic acidosis (LA) in patients receiving nucleoside reverse transcriptase inhibitors (NRTIs)
85. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment
86. Riboflavin to treat NRTI-induced lactic acidosis
87. Riboflavine and severe lactic acidosis
88. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature
89. Lactic acidosis, risk factors and therapeutic options
90. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine
91. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: A case report
92. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy
93. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
94. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
95. Metabolic complications and body fat redistribution in HIV-1 infected individuals: The fat redistribution syndrome
96. Protease inhibitor-associated hyperinsulinaemia
97. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
98. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analog therapy
99. Lipodystrophy in patients naive to HIV protease inhibitors
100. Lipodystrophy associated with nevirapine-containing antiretroviral therapies
101. A syndrome of lipodystrophy (LD), lactic acidaemia and liver dysfunction associated with HIV NRTI reverse transcriptase inhibitor therapy: A contribution to PI-related LD syndrome
102. Lack of clinical lipodystrophy in patients receiving efavirenz + NRTIs in study 006
103. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
104. Metabolic abnormalities and use of HIV-1 protease inhibitors
105. Fat accumulation and HIV-1 protease inhibitors
106. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
107. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
108. Protease inhibitors and NRTI reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection
109. Clinical factors related to lipodystrophy severity in the HIV Outpatient Study (HOPS)
110. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
111. Lipodystrophy related to NRT inhibitors in HAART therapy
112. Reversion of lipodystrophy after switching from HIV-1 protease inhibitors to nevirapine
113. A multi-center, randomized, open-label comparative trial of the clinical benefit of switching the protease inhibitor (PI) by nevirapine (NVP) in HAART-experienced patients suffering lipodystrophy
114. Management of indinavir-associated metabolic changes by substitution with efavirenz in virologically controlled HIV+ persons
115. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy
116. Switch to AZT+3TC improves lipodystrophy signs in the presence of protease inhibitors
117. The formation of respiratory chain complexes in mitochondria is under the proteolytic control of the m-AAA protease
118. Inhibition of adipocyte differentiation by HIV protease inhibitors
119. Fat distribution in AIDS
120. 'Buffalo hump' in men with HIV-1 infection
121. Benign symmetric lipomatosis associated with protease inhibitors
122. 'Buffalo hump' in HIV-1 infection
123. Mitochondrial dysfunction in multiple symmetrical lipomatosis
124. Multiple symmetric lipomatosis: Abnormalities in complex IV and multiple deletions in mitochondrial DNA
125. Defects of mitochondrial respiratory chain in multiple symmetric lipomatosis
126. Segregation and manifestations of the mtDNA tRNA(Lys) A→G(8344) mutation of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome
127. Clinical features associated with the A→G transition at nucleotide 8344 of mtDNA ('MERRF mutation')
128. Nuclear lamin A/C R482Q mutation in Canadian kindreds with Dunnigan-type familial partial lipodystrophy
129. Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety)
130. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34
131. Non-insulin-dependent diabetes mellitus as a mitochondrial genomic disease
132. Mitochondrial diabetes mellitus
133. Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit
134. Endocrine abnormalities in mitochondrial myopathy with external ophthalmoplegia
135. Using quantitative CT to assess adipose distribution in adult men with acquired hypogonadism
136. PPAR gamma is required for placental, cardiac, and adipose tissue development
137. Safety of antiprotease therapy after two episodes of lactic acidosis in an HIV-infected patient